Live Pharmaceutical Import data of Vietnam imports from china under HS Code 294190 via Port Cchq-ck-hai-phong-port-zone-i , our Vietnam customs import data reports include date, value, quantity, product description, HS code, port, country, and Vietnam pharmaceutical importers data
| Date |
HS Code |
Product Description |
Origin Country |
Custom Name |
QTY. |
Unit |
Value($) |
Importer Name |
|---|---|---|---|---|---|---|---|---|
| 2024-04-11 00:00:00 |
29419000
|
Spiramycin EP11 (Raw material for antibiotic production according to GPLH No. VD-28191-17); Batch No: 230935010M; Production: September 11, 2023 HD: September 10, 2026; Manufacturer: Topfond Pharmaceutical Co., Ltd - China | China | CCHQ CK Hai Phong Port Zone I | 100 | KGM | 22500 | Importer Name |
| 2024-04-11 00:00:00 |
29419000
|
Clindamycin Hydrochloride Current USP (nl produces antibiotics according to GPLH: VD-25845-16) Batch No: 20240225211; Production: February 25, 2024 HD: February 24, 2028; Manufacturer: Nanyang Pukang Pharmaceutical Co., Ltd. China. | China | CCHQ CK Hai Phong Port Zone I | 300 | KGM | 17550 | Importer Name |
| 2024-04-29 00:00:00 |
29419000
|
Fosfomycin Sodium: Powdered energy used to produce drugs, GPLH number: VD-34610-20. Manufacturer: Northeast Pharmaceutical Group Co., Ltd, EP11 standard. Lot number: DY1012400001. Production: December 2023. HD: December 2025. 100% New | China | CCHQ CK Hai Phong Port Zone I | 60 | KGM | 12600 | Importer Name |
| 2024-04-08 00:00:00 |
29419000
|
Acetylspiramycin CP2020 (raw material for producing Naphacogyl medicine according to GPLH: VD-26195-17); Batch No: 230931021; Production: September 8, 2023 HD: March 7, 2026; Producer: Topfond Pharmaceutical Co., Ltd - China | China | CCHQ CK Hai Phong Port Zone I | 100 | KGM | 10700 | Importer Name |
2024-04-11 00:00:00
Spiramycin EP11 (Raw material for antibiotic production according to GPLH No. VD-28191-17); Batch No: 230935010M; Production: September 11, 2023 HD: September 10, 2026; Manufacturer: Topfond Pharmaceutical Co., Ltd - China
100
KGM
22500
2024-04-11 00:00:00
Clindamycin Hydrochloride Current USP (nl produces antibiotics according to GPLH: VD-25845-16) Batch No: 20240225211; Production: February 25, 2024 HD: February 24, 2028; Manufacturer: Nanyang Pukang Pharmaceutical Co., Ltd. China.
300
KGM
17550
2024-04-29 00:00:00
Fosfomycin Sodium: Powdered energy used to produce drugs, GPLH number: VD-34610-20. Manufacturer: Northeast Pharmaceutical Group Co., Ltd, EP11 standard. Lot number: DY1012400001. Production: December 2023. HD: December 2025. 100% New
60
KGM
12600
2024-04-08 00:00:00
Acetylspiramycin CP2020 (raw material for producing Naphacogyl medicine according to GPLH: VD-26195-17); Batch No: 230931021; Production: September 8, 2023 HD: March 7, 2026; Producer: Topfond Pharmaceutical Co., Ltd - China
100
KGM
10700
The database includes shipment-level information such as shipment date, HS code, product description, quantity, value, port details, country of origin & destination, & importer-exporter information for accurate trade analysis of products under HS code 294190 for Vietnam pharmaceutical imports from Thailand via Port Cchq-ck-hai-phong-port-zone-i.
Port Cchq-ck-hai-phong-port-zone-i typically refers to a port that is used for handling and forwarding shipments into Vietnam, making it important for tracking inland and cross-border trade flows.
It helps businesses understand sourcing patterns, evaluate supplier performance, track pricing trends, and identify demand for pharmaceutical products, enabling better decision-making for trade and market expansion for Vietnam pharmaceutical imports from china under HS code 294190 via Port Cchq-ck-hai-phong-port-zone-i.
Businesses can identify key importers, evaluate supplier competitiveness, track pricing trends, and analyze demand for specific rubber products to make strategic sourcing and expansion decisions.
Importers, exporters, traders, manufacturers, and market analysts can use this data to understand trade patterns, optimize supply chains, identify potential partners, and gain a competitive advantage in the pharmaceutical market.
